{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:06:58Z","timestamp":1788912418847,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,8]]},"DOI":"10.7759\/cureus.115962","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:24:31Z","timestamp":1788909871000},"source":"Crossref","is-referenced-by-count":0,"title":["Nephrotic Syndrome During Ipilimumab Plus Nivolumab Therapy for Sarcomatoid Malignant Pleural Mesothelioma: A Case Report of Nivolumab Rechallenge Without Recurrence of Nephrotic Syndrome"],"prefix":"10.7759","author":[{"given":"Kazuhiro","family":"Shimaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoka","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar FB","year":"2020","unstructured":"Cortazar FB, Kibbelaar ZA, Glezerman IG, et al.. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol. 2020, 31:435-46. 10.1681\/ASN.2019070676","journal-title":"J Am Soc Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A systematic review of immune checkpoint inhibitor-associated glomerular disease","volume":"6","author":"Kitchlu A","year":"2021","unstructured":"Kitchlu A, Jhaveri KD, Wadhwani S, et al.. A systematic review of immune checkpoint inhibitor-associated glomerular disease. Kidney Int Rep. 2021, 6:66-77. 10.1016\/j.ekir.2020.10.002","journal-title":"Kidney Int Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-024-03494-1","article-title":"Nephrotic syndrome with acute kidney injury due to combination therapy of immune checkpoint inhibitors: a case report and review of the literature","volume":"25","author":"Saiki R","year":"2024","unstructured":"Saiki R, Katayama K, Saiki H, et al.. Nephrotic syndrome with acute kidney injury due to combination therapy of immune checkpoint inhibitors: a case report and review of the literature. BMC Nephrol. 2024, 25:51. 10.1186\/s12882-024-03494-1","journal-title":"BMC Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2025.2569089","article-title":"Immune checkpoint inhibitor-induced nephrotic syndrome: a pharmacovigilance analysis of 404 FAERS cases and literature case series","volume":"47","author":"Ye J","year":"2025","unstructured":"Ye J, Huang J, Shao L, Wang Z. Immune checkpoint inhibitor-induced nephrotic syndrome: a pharmacovigilance analysis of 404 FAERS cases and literature case series. Ren Fail. 2025, 47:2569089. 10.1080\/0886022X.2025.2569089","journal-title":"Ren Fail"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00258","article-title":"Treatment-related adverse events of combination immune checkpoint inhibitors: systematic review and meta-analysis","volume":"10","author":"Park R","year":"2020","unstructured":"Park R, Lopes L, Cristancho CR, Riano IM, Saeed A. Treatment-related adverse events of combination immune checkpoint inhibitors: systematic review and meta-analysis. Front Oncol. 2020, 10:258. 10.3389\/fonc.2020.00258","journal-title":"Front Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"Fadel F","year":"2009","unstructured":"Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med. 2009, 361:211-2. 10.1056\/NEJMc0904283","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2015.11.028","article-title":"Ipilimumab-associated minimal-change disease","volume":"89","author":"Kidd JM","year":"2016","unstructured":"Kidd JM, Gizaw AB. Ipilimumab-associated minimal-change disease. Kidney Int. 2016, 89:720. 10.1016\/j.kint.2015.11.028","journal-title":"Kidney Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.04.026","article-title":"Nephrotic syndrome with cancer immunotherapies: a report of 2 cases","volume":"70","author":"Kitchlu A","year":"2017","unstructured":"Kitchlu A, Fingrut W, Avila-Casado C, Chan CT, Crump M, Hogg D, Reich HN. Nephrotic syndrome with cancer immunotherapies: a report of 2 cases. Am J Kidney Dis. 2017, 70:581-5. 10.1053\/j.ajkd.2017.04.026","journal-title":"Am J Kidney Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk O","year":"2019","unstructured":"Mamlouk O, Selamet U, Machado S, et al.. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer. 2019, 7:2. 10.1186\/s40425-018-0478-8","journal-title":"J Immunother Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000519169","article-title":"IgA nephropathy secondary to ipilimumab use","volume":"11","author":"Dougherty SC","year":"2021","unstructured":"Dougherty SC, Desai N, Cathro HP, Renaghan A. IgA nephropathy secondary to ipilimumab use. Case Rep Nephrol Dial. 2021, 11:327-33. 10.1159\/000519169","journal-title":"Case Rep Nephrol Dial"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI189074","article-title":"CTLA-4 blockade shifts the B cell repertoire toward autoimmunity","volume":"135","author":"\u00c7akan E","year":"2025","unstructured":"\u00c7akan E, Wang M, Dai Y, et al.. CTLA-4 blockade shifts the B cell repertoire toward autoimmunity. J Clin Invest. 2025, 135:10.1172\/JCI189074","journal-title":"J Clin Invest"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1854177","article-title":"Severe renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in non-small cell lung cancer: a pharmacovigilance analysis of the FDA adverse event reporting system","volume":"17","author":"Cao J","year":"2026","unstructured":"Cao J, Peng L, Yang J, et al.. Severe renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in non-small cell lung cancer: a pharmacovigilance analysis of the FDA adverse event reporting system. Front Immunol. 2026, 17:1854177. 10.3389\/fimmu.2026.1854177","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/530460-nephrotic-syndrome-during-ipilimumab-plus-nivolumab-therapy-for-sarcomatoid-malignant-pleural-mesothelioma-a-case-report-of-nivolumab-rechallenge-without-recurrence-of-nephrotic-syndrome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:24:33Z","timestamp":1788909873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/530460-nephrotic-syndrome-during-ipilimumab-plus-nivolumab-therapy-for-sarcomatoid-malignant-pleural-mesothelioma-a-case-report-of-nivolumab-rechallenge-without-recurrence-of-nephrotic-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.115962","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,8]]}}}